Renal Outcomes in People With HIV-1 and Renal Impairment Treated With B/F/TAF: Integrated Analysis from Nine Phase 3/3b Clinical Trials
Abstract Among 1069 people with HIV-1 and mild to moderate renal impairment at baseline treated with bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) across nine clinical trials, renal function remained generally stable over follow-up of up to 240 weeks. Renal adverse events were infrequent, and discontinuation due to renal toxicity was rare.
Authors
- Indira Brar (ORCID: https://orcid.org/0000-0002-0568-6457)
- Samir Gupta (ORCID: https://orcid.org/0000-0002-7307-6247)
- D Wohl
- Jason T. Hindman (ORCID: https://orcid.org/0000-0003-1513-3423)
- Keith Aizen (ORCID: https://orcid.org/0009-0009-2763-8745)
- Frank A Post (ORCID: https://orcid.org/0000-0002-2844-1612)
- Geoffroy Liegeon (ORCID: https://orcid.org/0000-0003-1267-4347)
- Hui Liu
- Anchalee Avihingsanon
- Yazdan Yazdanpanah (ORCID: https://orcid.org/0009-0004-2402-643X)
- Debbie Hagins (ORCID: https://orcid.org/0000-0001-7478-7609)
Institutions
- University of North Carolina at Chapel Hill (US)
- Université Paris Cité (FR)
- Saint Louis University Hospital (US)
- Henry Ford Hospital (US)
- Assistance Publique – Hôpitaux de Paris (FR)
- King's College Hospital NHS Foundation Trust (GB)
- HIV Netherlands Australia Thailand Research Collaboration (TH)
- Memorial Health University Medical Center (US)
- Gilead Sciences (United States) (US)
- Hôpital Saint-Louis (FR)
- Hôpital Bichat-Claude-Bernard (FR)
- Indiana University School of Medicine
- Indiana University – Purdue University Indianapolis (US)
Publication Details
- Journal
- Open Forum Infectious Diseases
- Published
- 2026-05-01
- DOI
- https://doi.org/10.1093/ofid/ofag265
- Primary Topic
- HIV/AIDS drug development and treatment
- Type
- article
- Field-Weighted Citation Impact
- 0.00